Literature DB >> 23740815

Interferon-α induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis.

Imelda Balboni1, Timothy B Niewold, Gabrielle Morgan, Cindy Limb, Maija-Leena Eloranta, Lars Rönnblom, Paul J Utz, Lauren M Pachman.   

Abstract

OBJECTIVE: To evaluate serum interferon-α (IFNα) activity in the context of autoantibody profiles in patients with juvenile dermatomyositis (JDM).
METHODS: Sera from 36 patients with JDM were analyzed. Autoantibody profiles were determined by probing microarrays, which were fabricated with ∼80 distinct autoantigens, with serum and a Cy3-conjugated secondary antibody. Arrays were scanned and analyzed to determine antigen reactivity. Serum IFNα activity was measured using a functional reporter cell assay. Sera were assayed alone or in combination with cellular material released from necrotic U937 cells to stimulate peripheral blood mononuclear cells from healthy donors in vitro, and IFNα production in culture was measured by a dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA).
RESULTS: Reactivity against at least 1 of 41 autoantigens on the microarray, including Ro 52, Ro 60, La, Sm, and RNP, was observed in 75% of the serum samples from patients with JDM. IFNα activity was detected in 7 samples by reporter cell assay. The reporter cell assay showed a significant association of reactivity against Ro, La, Sm, and proliferating cell nuclear antigen with serum IFNα activity (P = 0.005). Significance Analysis of Microarrays (SAM) identified increased reactivity against Sm, RNP, Ro 52, U1-C, and Mi-2 in these sera. Sixteen samples induced IFNα production as measured by DELFIA, and there was a significant association of reactivity against Ro, La, Sm, and RNP with the induction of IFNα by serum and necrotic cell material (P = 0.034). SAM identified increased reactivity against Ro 60 in these sera.
CONCLUSION: These data support the hypothesis that nucleic acid-associated autoantibodies, including the Ro/La and Sm/RNP complexes, may stimulate the production of active IFNα in children with JDM.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23740815      PMCID: PMC4169271          DOI: 10.1002/art.38038

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  18 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Polymyositis and dermatomyositis (second of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-20       Impact factor: 91.245

3.  Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence.

Authors:  Rita K Bode; Marisa S Klein-Gitelman; Michael L Miller; Toula S Lechman; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2003-02-15

Review 4.  Anti-Mi-2 antibodies.

Authors:  Anna Ghirardello; Sandra Zampieri; Luca Iaccarino; Elena Tarricone; Raffaele Bendo; Pier Franca Gambari; Andrea Doria
Journal:  Autoimmunity       Date:  2005-02       Impact factor: 2.815

Review 5.  Multiplexed protein array platforms for analysis of autoimmune diseases.

Authors:  Imelda Balboni; Steven M Chan; Michael Kattah; Jessica D Tenenbaum; Atul J Butte; Paul J Utz
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

6.  The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer.

Authors:  U Båve; G V Alm; L Rönnblom
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

7.  Familial aggregation of autoimmune disease in juvenile dermatomyositis.

Authors:  Timothy B Niewold; Stephanie C Wu; Molly Smith; Gabrielle A Morgan; Lauren M Pachman
Journal:  Pediatrics       Date:  2011-04-18       Impact factor: 7.124

8.  Autoantigen microarrays for multiplex characterization of autoantibody responses.

Authors:  William H Robinson; Carla DiGennaro; Wolfgang Hueber; Brian B Haab; Makoto Kamachi; Erik J Dean; Sylvie Fournel; Derek Fong; Mark C Genovese; Henry E Neuman de Vegvar; Karl Skriner; David L Hirschberg; Robert I Morris; Sylviane Muller; Ger J Pruijn; Walther J van Venrooij; Josef S Smolen; Patrick O Brown; Lawrence Steinman; Paul J Utz
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

9.  Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis.

Authors:  Zivana Tezak; Eric P Hoffman; Jennica L Lutz; Tamara O Fedczyna; Dietrich Stephan; Eric G Bremer; Irina Krasnoselska-Riz; Ajit Kumar; Lauren M Pachman
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

10.  Immunogenetic studies of juvenile dermatomyositis. III. Study of antibody to organ-specific and nuclear antigens.

Authors:  L M Pachman; J M Friedman; M L Maryjowski-Sweeney; O Jonnason; R M Radvany; G C Sharp; M A Cobb; N D Battles; W E Crowe; C W Fink
Journal:  Arthritis Rheum       Date:  1985-02
View more
  15 in total

1.  Smith-Magenis Syndrome Patients Often Display Antibody Deficiency but Not Other Immune Pathologies.

Authors:  Tiffany Perkins; Jacob M Rosenberg; Carole Le Coz; Joseph T Alaimo; Melissa Trofa; Sureni V Mullegama; Richard J Antaya; Soma Jyonouchi; Sarah H Elsea; Paul J Utz; Eric Meffre; Neil Romberg
Journal:  J Allergy Clin Immunol Pract       Date:  2017-03-09

Review 2.  Antinuclear antibody testing - misunderstood or misbegotten?

Authors:  David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2017-05-25       Impact factor: 20.543

Review 3.  Type I Interferons in Autoimmunity.

Authors:  Ruth Fernandez-Ruiz; Timothy B Niewold
Journal:  J Invest Dermatol       Date:  2022-01-10       Impact factor: 8.551

Review 4.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 5.  The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.

Authors:  Consuelo M López de Padilla; Timothy B Niewold
Journal:  Gene       Date:  2015-09-26       Impact factor: 3.688

Review 6.  The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.

Authors:  L G Rider; K Nistala
Journal:  J Intern Med       Date:  2016-03-30       Impact factor: 8.989

Review 7.  New autoantibody detection technologies yield novel insights into autoimmune disease.

Authors:  Peter D Burbelo; Terrance P O'Hanlon
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

8.  Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.

Authors:  Theresa Wampler Muskardin; Priyanka Vashisht; Jessica M Dorschner; Mark A Jensen; Beverly S Chrabot; Marlena Kern; Jeffrey R Curtis; Maria I Danila; Stacey S Cofield; Nancy Shadick; Peter A Nigrovic; E William St Clair; Clifton O Bingham; Richard Furie; William Robinson; Mark Genovese; Christopher C Striebich; James R O'Dell; Geoffrey M Thiele; Larry W Moreland; Marc Levesque; S Louis Bridges; Peter K Gregersen; Timothy B Niewold
Journal:  Ann Rheum Dis       Date:  2015-11-06       Impact factor: 19.103

Review 9.  Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Authors:  Lisa G Rider; Katalin Dankó; Frederick W Miller
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

10.  Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus.

Authors:  D James Haddon; Vivian K Diep; Jordan V Price; Cindy Limb; Paul J Utz; Imelda Balboni
Journal:  Arthritis Res Ther       Date:  2015-06-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.